In addition, objective responses with ipilimumab plus nivolumab were achieved in patients with primary resistance to anti-PD-(L)1 therapy, adding to growing preclinical and clinical evidence that combined PD-(L)1/CTLA-4 blockade can overcome PD-(L)1 resistance in HCC and other tumor types (10, 13). This evidence concerns the gene CD274 and neoplasm.